Evidence map›Paper›PMID 41344698›Full record

ArticleGut2026

Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection.

Anucha Preechanukul, Aljawharah Alrubayyi, Bo Sun, Edward Arbe-Barnes, Jonida Kokici, Frances Gorou, Sarun Prasitdumrong, Kelly A S da Costa, Natasha Fisher-Pearson, Noshin Hussain and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Anucha PreechanukulInstitute of Immunity and Transplantation, University College London, London, UK.ORCID http://orcid.org/0000-0001-7428-0058
Aljawharah AlrubayyiNuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Bo SunNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Edward Arbe-BarnesInstitute of Immunity and Transplantation, University College London, London, UK.
Jonida KokiciInstitute of Immunity and Transplantation, University College London, London, UK.
Frances GorouInstitute of Immunity and Transplantation, University College London, London, UK.
Sarun PrasitdumrongInstitute of Immunity and Transplantation, University College London, London, UK.
Kelly A S da CostaInstitute of Immunity and Transplantation, University College London, London, UK.
Natasha Fisher-PearsonNuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
Noshin HussainInstitute of Immunity and Transplantation, University College London, London, UK.
Stephanie KucykowiczInstitute of Immunity and Transplantation, University College London, London, UK.
Indrajit GhoshMortimer Market Clinic, Central Northwest London NHS Foundation Trust, London, UK.
Fiona BurnsDepartment of HIV Medicine, Royal Free London NHS Foundation Trust, London, UK.
Sabine KinlochDepartment of HIV Medicine, Royal Free London NHS Foundation Trust, London, UK.
Pedro SimoesDepartment of HIV Medicine, Royal Free London NHS Foundation Trust, London, UK.
Sanjay BhaganiDepartment of HIV Medicine, Royal Free London NHS Foundation Trust, London, UK.
Patrick T F KennedyBarts Liver Centre, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0001-9201-0094
Mala K MainiInstitute of Immunity and Transplantation, University College London, London, UK.ORCID http://orcid.org/0000-0001-6384-1462
Rachael Bashford-RogersDepartment of Biochemistry, University of Oxford, Oxford, UK.
Upkar S GillBarts Liver Centre, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Dimitra PeppaInstitute of Immunity and Transplantation, University College London, London, UK d.peppa@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9281-5471

Funding

Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradicationR01AI155182 · NIAID · UNIVERSITY OF OXFORD · PI PEPPA, DIMITRA · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI155182
6 · The paper itself

Abstract

backgroundChronic hepatitis B virus (HBV) infection disproportionately affects people living with HIV, who are often excluded from functional cure studies.

objectiveThis study investigates CD8

designWe analysed CD8

resultsTranscriptomic analysis revealed distinct signatures in co-infection, with upregulation of TCR signalling genes, inhibitory pathways and progenitor-exhausted markers (

conclusionsPeople with well-controlled HBV/HIV co-infection maintain robust CD8

Indexed as

CD8-Positive T-LymphocytesCoinfectionHepatitis B, ChronicHepatitis B virusHIV InfectionsAdultAntiviral AgentsFemaleHumansMaleMiddle AgedProteomicsT-Cell ExhaustionAntiviral AgentsCELLULAR IMMUNITYCHRONIC VIRAL HEPATITISHEPATITIS BIMMUNE RESPONSEIMMUNOLOGY

Identifiers

PMID41344698
PMCPMC12848322

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.